Mahmoud Ismayl, M.D.
@Mahmoud_Ismayl
Followers
6K
Following
767
Media
41
Statuses
1K
Chief Cardiology Fellow & Asst. Prof. @MayoClinic | Outcomes & Disparity Research | Educator @CardiologyUniv | Lifelong learner | Interventional & Structural.
Rochester, MN
Joined August 2011
I’m truly honored and grateful to serve as Chief Fellow alongside @dinubalanescu and @Dobeze_. Excited for the year ahead and the opportunity to contribute to the continued success and growth of our cardiology fellowship at @MayoClinic.
11
8
164
@Mahmoud_Ismayl @MayraGuerreroMD @nandananavekar @AGoldsweig @MayoCVFellows @MayoClinicCV @MayoClinic Best co-fellows 💪🏻 @Mahmoud_Ismayl @LuaiMadanat looking forward to argue about stent sizing soon! 😍😍😍 @MayoCVFellows
0
1
11
You could be here by Friday for a weekend of sun salutations
1
0
9
Absolutely honored and thrilled to be staying at Mayo Clinic for Interventional Cardiology Fellowship!! 🫀🎉 Extremely grateful for everyone who supported me along the way! #Match2026 #CardioX
44
38
1K
Congratulations @Mahmoud_Ismayl for this important analysis! No doubt that TAVR utilization in patients aged 50-64 years is increasing rapidly in the US despite lack of randomized clinical trial data evaluating SAVR or TAVR in these group of patients. It is time! We need a
Happy to share our 📜 on #TAVR vs. #SAVR in pts aged 50-64 yrs published @MyJSCAI TAVR is 📈 perfomed in pts aged 50-64 yrs (~42% of AVR’s in 2021) w/: ⬇️ In-hospital ☠️, stroke 🧠, AKI ⬆️ PPM & 180-day 🏥 🔗 Link: https://t.co/2zBFUwt6Ng 🔗 Editorial: https://t.co/COA8OPcBhX
3
9
53
Happy to share our 📜 on #TAVR vs. #SAVR in pts aged 50-64 yrs published @MyJSCAI TAVR is 📈 perfomed in pts aged 50-64 yrs (~42% of AVR’s in 2021) w/: ⬇️ In-hospital ☠️, stroke 🧠, AKI ⬆️ PPM & 180-day 🏥 🔗 Link: https://t.co/2zBFUwt6Ng 🔗 Editorial: https://t.co/COA8OPcBhX
4
4
37
The Isolator® Synergy™ EnCompass® Clamp is designed to make surgical ablations more efficient and easier to perform without compromising a transmural and contiguous lesion.
8
11
119
Strong work @Mahmoud_Ismayl as always! I'm so proud of you!!!
Grateful for an incredible experience at #TCT2025 — from presenting our latest research to connecting with mentors and catching up with friends. Huge thanks to @TCTMD @crfheart @MayoClinicCV @MayoCVFellows
1
1
31
Extremely proud of my fellows. I stand well within their shadows as they pave the path forward to the next frontier. @MayoCVFellows @MayoClinicCV
Grateful for an incredible experience at #TCT2025 — from presenting our latest research to connecting with mentors and catching up with friends. Huge thanks to @TCTMD @crfheart @MayoClinicCV @MayoCVFellows
0
4
62
Grateful for an incredible experience at #TCT2025 — from presenting our latest research to connecting with mentors and catching up with friends. Huge thanks to @TCTMD @crfheart @MayoClinicCV @MayoCVFellows
3
7
65
Excited to share our #JACCINT manuscript reporting clinical outcomes of #LAAO vs #Apixaban vs #Warfarin in 14,849 patients with #Afib and #ESRD🫀👇🏽 Tremendously grateful to @adnanalkhouli’s support and mentorship! https://t.co/YUN78ZzKET
#CardioX @JACCJournals
4
22
83
You don’t build a strong life by accident. You build it through discipline, faith, and the hard work no one else sees. I’ve rebuilt myself more times than I like to admit — as a husband, a father, a leader, and a man. Here, I teach what actually works: • Discipline that
9
3
29
In our latest @JACCJournals article, we show that IVI-guided PCI reduces MACE in both men & women—with no sex interaction. Yet, women remain underrepresented in IVI trials (23.9%). It’s time to close the gap. https://t.co/pN92hG7E3f
3
14
55
Happy to share our paper on cardiogenic shock with acute myocardial infarction in older adults in the US published 🫀@JACCJournals #JACCADV 🔗: https://t.co/0nCmCZZi9m
@AliBAbdulJabbar @Mahmoud_Ismayl @krtkgpt @SachinParikhMD @AbdulMannan5465 @DmitryAbramovMD @virani_md
2
8
55
Strong work! So far, the data doesn’t suggest benefit of routine use. Perhaps a subset of patients may benefit, this needs to be defined.
Happy to share our updated meta-analysis of RCT’s on cerebral embolic protection (CEP) during #TAVR following the BHF PROTECT-TAVI trial #CEP use was associated with: ↔️ Stroke and disabling stroke 🧠 ↔️ All-cause mortality ☠️ @MayoProceedings 🔗 Link: https://t.co/PpXGgzKn9z
2
7
42
Happy to share our updated meta-analysis of RCT’s on cerebral embolic protection (CEP) during #TAVR following the BHF PROTECT-TAVI trial #CEP use was associated with: ↔️ Stroke and disabling stroke 🧠 ↔️ All-cause mortality ☠️ @MayoProceedings 🔗 Link: https://t.co/PpXGgzKn9z
5
3
41
We are proud that Mayo Clinic has been recognized once again as a leader in healthcare, a reflection of the unwavering commitment of our staff and their dedication to excellence, innovation, and putting patients first. https://t.co/lKCcbijUcG
9
61
244
Our comprehensive review on novel hypertriglyceridemia treatments to address ASCVD published in the American Journal of Cardiovascular Drugs 🫀 @AbdulMannan5465 @virani_md @DmitryAbramovMD @Mahmoud_Ismayl @SachinParikhMD @arunima_misra 🔗: https://t.co/gYyTYyfrZC
1
8
30
I’m so proud of our superstar fellow @Mahmoud_Ismayl … presenting at New York Valves 2 years in a row!!! @MayoClinicCV
Had a great time at #NYValves2025, from showcasing our latest research to connecting with mentors and catching up with friends! Thank you @crfheart @MayoClinicCV @MayoCVFellows
1
3
70
Had a great time at #NYValves2025, from showcasing our latest research to connecting with mentors and catching up with friends! Thank you @crfheart @MayoClinicCV @MayoCVFellows
4
3
72
PET imaging with coronary flow reserve offers an excellent first-line noninvasive modality for diagnosis of coronary microvascular dysfunction. https://t.co/AlN1feRO4h
0
3
14
@MayoClinicCV is proud to announce the next generation of Chief 🫀 @MayoCVFellows: Dr. @dinubalanescu, Dr. @Dobeze_, and Dr. @Mahmoud_Ismayl! We’re excited for them to greet the incoming class and take our program to the next level.
4
4
32
@MayoClinicCV is proud to announce the next generation of Chief 🫀 @MayoCVFellows: Dr. @dinubalanescu, Dr. @Dobeze_, and Dr. @Mahmoud_Ismayl! We’re excited for them to greet the incoming class and take our program to the next level.
1
7
53